Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818349 | 0.87 | CREBBP (0.44) | CREBBPBRD4EP300MAPK1HCAR2 | |
| SCHEMBL18880484 | 0.86 | MAPK1 (0.47) | CREBBPBRD4EP300MAPK1AURKA | |
| SCHEMBL21995304 | 0.85 | CCNA2 (0.39) | P2RX7CREBBPBRD4EP300AURKA | |
| SCHEMBL16127191 | 0.82 | CREBBP (0.52) | P2RX7CREBBPBRD4EP300MAPK1 | |
| SCHEMBL22541359 | 0.82 | P2RX7 (0.49) | P2RX7AURKACCNA2CDK2CCNA1 | |
| SCHEMBL28646727 | 0.81 | P2RX7 (0.39) | P2RX7CREBBPBRD4EP300MAPK1 | |
| SCHEMBL28644919 | 0.81 | CREBBP (0.41) | P2RX7CREBBPBRD4EP300MAPK1 | |
| SCHEMBL28645366 | 0.79 | RBP4 (0.43) | P2RX7CREBBPBRD4EP300MAPK1 | |
| SCHEMBL17317597 | 0.79 | ADORA1 (0.44) | MAPK1RBP4 | |
| SCHEMBL23881426 | 0.77 | P2RX7 (0.37) | P2RX7CREBBPBRD4EP300MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | P2RX7 1223/4885CREBBP 1508/4885BRD4 681/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | P2RX7 1224/4885CREBBP 1504/4885BRD4 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.